2023-2030 年大分子藥物 CDMO 行業分析、規模、份額、增長、趨勢和預測的全球市場研究報告

全球對大分子藥物CDMO市場的需求將從2022年的227.1億美元增長到2030年的約579.4億美元，2023年至2030年調查期間複合年增長率為12.42%，預計將達到

大分子藥物 CDMO 是合同開發和製造組織 (CDMO)，提供加工大分子藥物的服務。 大分子高度複雜，具有治療作用，並且製備得與人類蛋白質相似。 它是分子製造的關鍵步驟之一。 我們通過為客戶提供從藥物開發到製造的服務來支持製藥行業。 CDMO 通過提供知識、開發和製造能力以及整合第三方項目來提供基本服務。

市場動態：

推動大分子CDMO市場需求的主要因素是傳染病患者的增加。 FDA 對大分子藥物的批准增加有助於該市場的增長。 由於慢性病的增加，對藥品的需求不斷增長，這推動了市場需求。 預計在預測期內，技術的不斷進步、資本投資的增加以及製藥和生物技術公司與 CDMO 之間合作夥伴關係的建立將為該市場帶來若干增長機會。 與生物製劑和生物仿製藥相關的研發活動的增加正在增加對該市場的需求。 心血管疾病和 CVD 死亡率的增加推動了對該市場的需求。 然而，嚴格的政府法規可能會阻礙該市場的增長。

這份研究報告描述了波特的五力模型、市場吸引力分析和價值鏈分析。 這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。 此外，這些工具還能夠全面評估全球大分子原料藥cdmo市場的各個細分市場。 大分子藥物 cdmo 行業的增長和趨勢為這項研究提供了一個整體方法。

市場細分：

本部分提供按國家和地區細分的詳細數據，以幫助您確定您的產品或服務的目標受眾和未來商機。

按服務

• 合同製造（臨床、商業）
• 合同開發（細胞系開發、工藝開發）

按供應商

• 哺乳動物
• 微生物
• 其他

由最終用戶

• 生物技術公司
• 首席風險官
• 其他

按地區分析：

本節提供了北美、歐洲、亞太地區、拉丁美洲、中東和非洲對大型原料藥 CDMO 市場當前和未來需求的區域展望。 它還側重於所有主要地區的各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。 大分子藥物 cdmo 市場的主要參與者是 Eurofins Scientific、WuXi Biologics、Samsung Biologics、Catalent, Inc、Rentschler Biopharma SE、AGC Biologics、Recipharm AB、Siegfried Holding AG、Boehringer Ingelheim 和 Fujifilm Diosynth Biotechnologies。 本節概述了競爭格局，包括各種戰略發展，例如主要併購、未來能力、合作夥伴關係、財務概覽、合作、新產品開發和新產品發布。

如果您有定制要求，請聯繫我們。 我們的研究團隊可以根據您的需要提供定制報告。

內容

第一章前言

• 本報告的內容
  • 目的
  • 目標受眾
  • 獨特的銷售建議 (USP) 和提供的服務
• 調查範圍
• 調查方法
  • 市場調研過程
  • 市場研究方法

第 2 章執行摘要

• 市場亮點
• 全球市場概況

第三章大分子藥物CDMO-產業分析

• 簡介 - 市場動態
• 市場驅動因素
• 市場製約因素
• 市場機會
• 行業趨勢
• 波特的五力分析
• 市場吸引力分析
  • 按服務分類的市場吸引力分析
  • 按來源進行市場吸引力分析
  • 按市場進行的吸引力分析：按最終用戶
  • 市場吸引力分析：按地區

第四章價值鏈分析

• 價值鏈分析
• 原材料分析
  • 成分錶
  • 原材料製造商列表
  • 主要原材料價格走勢
• 潛在買家名單
• 營銷渠道
  • 直接營銷
  • 間接營銷
  • 營銷渠道趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章大分子 CDMO 的全球市場分析：按服務分類

• 服務概覽
• 實際數據和預測數據
• 服務分析
• 合同製造（臨床、商業）
• 委託開發（細胞系開發、工藝開發）

第 7 章全球大分子 CDMO 市場分析：按供應商

• 按來源匯總
• 實際數據和預測數據
• 來源分析
• 哺乳動物
• 微生物
• 其他

第 8 章大分子藥物 CDMO 的全球市場銷售分析：按最終用戶分類

• 最終用戶總結
• 實際數據和預測數據
• 最終用戶分析
• 生物技術公司
• 首席風險官
• 其他

第9章大分子原料藥cdmo全球市場銷售分析：按地區

• 按地區進行的銷售分析
• 介紹銷售分析
• 北美銷售分析
  • 概覽、歷史和預測銷售分析
  • 北美各部門的銷售分析
  • 北美銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史和預測銷售分析
  • 按細分市場進行的歐洲銷售分析
  • 按國家/地區劃分的歐洲銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 意大利銷售分析
  • 俄羅斯銷售分析
  • 其他歐洲銷售分析
• 亞太地區銷售分析
  • 概覽、歷史和未來銷售分析
  • 亞太地區各部門的銷售分析
  • 亞太國家/地區銷售分析
  • 在中國的銷售分析
  • 印度銷售分析
  • 日本的銷售分析
  • 韓國銷售分析
  • 澳大利亞銷售分析
  • 其他亞太地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史和未來銷售分析
  • 拉丁美洲各部門的銷售分析
  • 拉丁美洲國家/地區的銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利的銷售分析
  • 其他拉丁美洲銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史和未來銷售分析
  • 中東/非洲地區的銷售分析
  • 中東和非洲國家/地區的銷售分析
  • 沙特阿拉伯銷售分析
  • 阿聯酋銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 其他中東和非洲銷售分析

第10章高分子藥物CDMO企業競爭格局

• 大分子原料藥 Cdmo 的市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第11章公司簡介

• 前 10 名公司的市場份額分析
• 市場集中度
• 歐陸科學
  • 公司簡介
  • 企業收入
  • 產品介紹
  • 近期發展狀況
• 藥明生物
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• 三星生物製品
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• 康泰倫特公司
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• Rentschler Biopharma SE
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• AGC 生物製劑
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• Recipharm AB
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• 齊格弗裡德控股公司
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• 勃林格殷格翰
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期發展狀況
• Fujifilm Diosynth Biotechnologies
  • 公司簡介
  • 企業收入
  • 產品信息
  • 近期趨勢

注意：公司簡介中的財務細節和近期發展基於可用信息，可能不包括私營公司。

The global demand for Large Molecule Drug Substance CDMO Market is presumed to reach the market size of nearly USD 57.94 BN by 2030 from USD 22.71 BN in 2022 with a CAGR of 12.42% under the study period 2023 - 2030.

Large molecule drug substance CDMO refers to the contract development and manufacturing orGaNizations (CDMO) which provide services for processing large molecule drug substances. Large molecules are highly complex, have therapeutic effects and are prepared to resemble human proteins. It is one of the important steps for molecule production. It provides customers with services from drug development to manufacturing and, thus, assists the pharmaceutical industry. CDMO offers knowledge, development and manufacturing capabilities and provides crucial services by incorporating third-party projects. 

Market Dynamics:

The key factor driving the demand for large molecule drug substance CDMO market is the rising cases of infectious diseases. Increasing large molecule drug approvals with FDA are contributing to the growth of this market. The growing pharmaceutical products demand due to the rising incidence of chronic diseases is surging the demand for this market. Continuous advancement in technology, increasing capital investment and establishment of partnerships by Pharma as well as biotech firms with CDMOs are expected to create several growth opportunities for this market over the forecast period. The rise in research and development activities associated with biologics and biosimilars is augmenting the demand for this market. Growth in cardiovascular diseases and CVD-induced deaths propel the demand for this market. However, stringent government regulations may obstruct the growth of this market. 

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of large molecule drug substance cdmo. The growth and trends of large molecule drug substance cdmo industry provide a holistic approach to this study. 

Market Segmentation:

This section of the large molecule drug substance cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Service

• Contract Manufacturing (Clinical, Commercial)
• Contract Development (Cell Line Development, Process Development)

By Source

• Mammalian
• Microbial
• Others

By End-User

• Biotech Companies
• CRO
• Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Large Molecule Drug Substance CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the large molecule drug substance cdmo market include Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . LARGE MOLECULE DRUG SUBSTANCE CDMO - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Service
  • 3.7.2 Market Attractiveness Analysis By Source
  • 3.7.3 Market Attractiveness Analysis By End-user
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SERVICE

• 6.1 Overview by Service
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Service
• 6.4 Contract Manufacturing (Clinical, Commercial) Historic and Forecast Sales by Regions
• 6.5 Contract Development (Cell Line Development, Process Development) Historic and Forecast Sales by Regions

7 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SOURCE

• 7.1 Overview by Source
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Source
• 7.4 Mammalian Historic and Forecast Sales by Regions
• 7.5 Microbial Historic and Forecast Sales by Regions
• 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET SALES ANALYSIS BY END-USER

• 8.1 Overview by End-user
• 8.2 Historical and Forecast Data
• 8.3 Analysis by End-user
• 8.4 Biotech Companies Historic and Forecast Sales by Regions
• 8.5 CRO Historic and Forecast Sales by Regions
• 8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET SALES ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook Sales Analysis
• 9.2. Introduction Sales Analysis
• 9.3. North America Sales Analysis
  • 9.3.1. Overview, Historic and Forecast Sales Analysis
  • 9.3.2. North America By Segment Sales Analysis
  • 9.3.3. North America By Country Sales Analysis
  • 9.3.4. United State Sales Analysis
  • 9.3.5. Canada Sales Analysis
  • 9.3.6. Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1. Overview, Historic and Forecast Sales Analysis
  • 9.4.2. Europe by Segment Sales Analysis
  • 9.4.3. Europe by Country Sales Analysis
  • 9.4.4. United Kingdom Sales Analysis
  • 9.4.5. France Sales Analysis
  • 9.4.6. Germany Sales Analysis
  • 9.4.7. Italy Sales Analysis
  • 9.4.8. Russia Sales Analysis
  • 9.4.9. Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1. Overview, Historic and Forecast Sales Analysis
  • 9.5.2. Asia Pacific by Segment Sales Analysis
  • 9.5.3. Asia Pacific by Country Sales Analysis
  • 9.5.4. China Sales Analysis
  • 9.5.5. India Sales Analysis
  • 9.5.6. Japan Sales Analysis
  • 9.5.7. South Korea Sales Analysis
  • 9.5.8. Australia Sales Analysis
  • 9.5.9. Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1. Overview, Historic and Forecast Sales Analysis
  • 9.6.2. Latin America by Segment Sales Analysis
  • 9.6.3. Latin America by Country Sales Analysis
  • 9.6.4. Brazil Sales Analysis
  • 9.6.5. Argentina Sales Analysis
  • 9.6.6. Peru Sales Analysis
  • 9.6.7. Chile Sales Analysis
  • 9.6.8. Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1. Overview, Historic and Forecast Sales Analysis
  • 9.7.2. Middle East & Africa by Segment Sales Analysis
  • 9.7.3. Middle East & Africa by Country Sales Analysis
  • 9.7.4. Saudi Arabia Sales Analysis
  • 9.7.5. UAE Sales Analysis
  • 9.7.6. Israel Sales Analysis
  • 9.7.7. South Africa Sales Analysis
  • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE LARGE MOLECULE DRUG SUBSTANCE CDMO COMPANIES

• 10.1. Large Molecule Drug Substance Cdmo Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11 . COMPANY PROFILES OF LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY

• 11.1. Top 10 Company Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Eurofins Scientific
  • 11.3.1. Company Overview
  • 11.3.2. Company Revenue
  • 11.3.3. Products
  • 11.3.4. Recent Developments
• 11.4. WuXi Biologics
  • 11.4.1. Company Overview
  • 11.4.2. Company Revenue
  • 11.4.3. Products
  • 11.4.4. Recent Developments
• 11.5. Samsung Biologics
  • 11.5.1. Company Overview
  • 11.5.2. Company Revenue
  • 11.5.3. Products
  • 11.5.4. Recent Developments
• 11.6. Catalent Inc.
  • 11.6.1. Company Overview
  • 11.6.2. Company Revenue
  • 11.6.3. Products
  • 11.6.4. Recent Developments
• 11.7. Rentschler Biopharma SE
  • 11.7.1. Company Overview
  • 11.7.2. Company Revenue
  • 11.7.3. Products
  • 11.7.4. Recent Developments
• 11.8. AGC Biologics
  • 11.8.1. Company Overview
  • 11.8.2. Company Revenue
  • 11.8.3. Products
  • 11.8.4. Recent Developments
• 11.9. Recipharm AB
  • 11.9.1. Company Overview
  • 11.9.2. Company Revenue
  • 11.9.3. Products
  • 11.9.4. Recent Developments
• 11.10. Siegfried Holding AG
  • 11.10.1. Company Overview
  • 11.10.2. Company Revenue
  • 11.10.3. Products
  • 11.10.4. Recent Developments
• 11.11. Boehringer Ingelheim
  • 11.11.1. Company Overview
  • 11.11.2. Company Revenue
  • 11.11.3. Products
  • 11.11.4. Recent Developments
• 11.12. Fujifilm Diosynth Biotechnologies
  • 11.12.1. Company Overview
  • 11.12.2. Company Revenue
  • 11.12.3. Products
  • 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Service (USD MN)
• Contract Manufacturing (Clinical, Commercial) Market Sales by Geography (USD MN)
• Contract Development (Cell Line Development, Process Development) Market Sales by Geography (USD MN)
• Analysis Market by Source (USD MN)
• Mammalian Market Sales by Geography (USD MN)
• Microbial Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis by End-user (USD MN)
• Biotech Companies Market Sales by Geography (USD MN)
• CRO Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Large Molecule Drug Substance Cdmo Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Large Molecule Drug Substance Cdmo Report
• Market Research Process
• Market Research Methodology
• Global Large Molecule Drug Substance Cdmo Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Service
• Market Attractiveness Analysis by Source
• Market Attractiveness Analysis by End-user
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Service (USD MN)
• Contract Manufacturing (Clinical, Commercial) Market Sales by Geography (USD MN)
• Contract Development (Cell Line Development, Process Development) Market Sales by Geography (USD MN)
• Global Market Analysis by Source (USD MN)
• Mammalian Market Sales by Geography (USD MN)
• Microbial Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by End-user (USD MN)
• Biotech Companies Market Sales by Geography (USD MN)
• CRO Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.